• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Scholar Rock Holding Corporation (Amendment)

    2/14/24 4:26:22 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRRK alert in real time by email
    SC 13G/A 1 tm245846d16_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 7)

     

    Scholar Rock Holding Corporation

     

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

     

    (Title of Class of Securities)

     

    80706P103

     

     

    (CUSIP Number)

     

    December 31, 2023

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨   Rule 13d-1(b)

     

    x   Rule 13d-1(c)

     

    ¨   Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 80706P103

    1

    Name of Reporting Person

     

    Redmile Group, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3 SEC Use Only
    4

    Citizenship or Place of Organization

    Delaware

     

     

     

    number of shares beneficially owned by each reporting person with

     

     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,706,883 (1)

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,706,883 (1)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,706,883 (1)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.9%(2)

    12

    Type of Reporting Person (See Instructions)

     

    IA, OO

     

     

    (1) Redmile Group, LLC’s beneficial ownership of the Issuer’s common stock (“Common Stock”) is comprised of 6,402,505 shares of Common Stock owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC (the “Redmile Funds”), including RedCo II Master Fund, L.P. and Redmile Strategic Trading Sub, Ltd., which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Subject to the Beneficial Ownership Blocker (as defined below), Redmile Group, LLC may also be deemed to beneficially own 12,712,595 shares of Common Stock issuable upon exercise of certain Warrants to Purchase Common Stock (the “Warrants”). Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, to the extent that, after giving effect to the attempted exercise set forth in a notice of exercise, such holder, together with such holder’s affiliates and any other person whose beneficial ownership of Common Stock would be aggregated with such holder’s for the purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the applicable regulations of the Securities and Exchange Commission (the “SEC”), including any “group” of which such holder is a member, would beneficially own a number of shares of Common Stock in excess of the Beneficial Ownership Limitation (the “Beneficial Ownership Blocker”). The “Beneficial Ownership Limitation” is 9.99% of the shares of Common Stock then issued and outstanding, which percentage may be changed at a holder’s election upon 61 days’ notice to the Issuer. The 7,706,883 shares of Common Stock reported as beneficially owned by Redmile Group, LLC in this Schedule 13G represents 9.99% of the outstanding shares of Common Stock (calculated in accordance with footnote (2) below).

    (2) Percentage based on (i) 72,143,258 shares of Common Stock outstanding as of November 2, 2023, as reported by the Issuer in its Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 7, 2023 (the “Form 10-Q”), plus (ii) 1,304,378 shares of Common Stock issuable upon exercise of certain of the Warrants, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of the Warrants, plus (iii) 3,698,343 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 2, 2023 to December 31, 2023.

     

     

     

     

    CUSIP No. 80706P103

    1

    Name of Reporting Person

     

    Jeremy C. Green

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3 SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    United Kingdom

     

     

     

     

    number of shares beneficially owned by each reporting person with

     

     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    7,706,883 (3)

     

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    7,706,883 (3)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    7,706,883 (3)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    9.9%(4)

    12

    Type of Reporting Person (See Instructions)

     

    IN, HC

     

     

    (3) Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 6,402,505 shares of Common Stock owned by the Redmile Funds, including RedCo II Master Fund, L.P. and Redmile Strategic Trading Sub, Ltd., which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Subject to the Beneficial Ownership Blocker, Mr. Green may also be deemed to beneficially own 12,712,595 shares of Common Stock issuable upon exercise of the Warrants. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The 7,706,883 shares of Common Stock reported as beneficially owned by Redmile Group, LLC in this Schedule 13G represents 9.99% of the outstanding shares of Common Stock (calculated in accordance with footnote (4) below).

    (4) Percentage based on (i) 72,143,258 shares of Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q, plus (ii) 1,304,378 shares of Common Stock issuable upon exercise of certain of the Warrants, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of the Warrants, plus (iii) 3,698,343 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 2, 2023 to December 31, 2023.

     

     

     

     

    CUSIP No. 80706P103

    1

    Name of Reporting Person

     

    RedCo II Master Fund, L.P.

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3 SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Cayman Islands

     

     

     

     

    number of shares beneficially owned by each reporting person with

     

     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    3,209,901 (5)

     

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    3,209,901 (5)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    3,209,901 (5)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    4.2%(6)

    12

    Type of Reporting Person (See Instructions)

     

    PN

     

     

    (5) RedCo II Master Fund, L.P.’s beneficial ownership of the Issuer’s Common Stock is comprised of 1,905,523 shares of Common Stock. Subject to the Beneficial Ownership Blocker, RedCo II Master Fund, L.P. also beneficially owns 10,655,102 shares of Common Stock issuable upon exercise of the Warrants directly held by RedCo II Master Fund, L.P. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The shares of Common Stock reported as beneficially owned by RedCo II Master Fund, L.P. in this Schedule 13G represent the shares of Common Stock held directly by RedCo II Master Fund, L.P. and the 1,304,378 shares of Common Stock that could be issued to RedCo II Master Fund, L.P. upon exercise of certain of the Warrants directly held by RedCo II Master Fund, L.P. under the Beneficial Ownership Blocker.

    (6) Percentage based on: (i) 72,143,258 shares of Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 1,304,378 shares of Common Stock issuable upon exercise of certain of the Warrants, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of the Warrants, plus (iii) 3,698,343 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 2, 2023 to December 31, 2023.

     

     

     

     

    CUSIP No. 80706P103

    1

    Name of Reporting Person

     

    Redmile Strategic Trading Sub, Ltd.

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)  ¨

    (b)  ¨

    3 SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    Cayman Islands

     

     

     

     

    number of shares beneficially owned by each reporting person with

     

     

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    897,112 (7)

     

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    897,112 (7)

     

    9

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    897,112 (7)

    10

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

    11

    Percent of Class Represented by Amount in Row (9)

     

    1.2%(8)

    12

    Type of Reporting Person (See Instructions)

     

    CO

     

     

    (7) Redmile Strategic Trading Sub, Ltd. beneficially owns 491,939 shares of Common Stock and 405,173 shares of Common Stock issuable upon exercise of the Warrants directly held by Redmile Strategic Trading Sub, Ltd.

    (8) Percentage based on: (i) 72,143,258 shares of Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 405,173 shares of Common Stock issuable upon exercise of certain of the Warrants, plus (iii) 3,698,343 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 2, 2023 to December 31, 2023.

     

     

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Scholar Rock Holding Corporation

     

    (b) Address of Issuer’s Principal Executive Offices

     

    301 Binney Street, 3rd Floor

    Cambridge, MA 02142

     

    Item 2.

     

    (a) Names of Persons Filing

     

    Redmile Group, LLC

    Jeremy C. Green

    RedCo II Master Fund, L.P.

    Redmile Strategic Trading Sub, Ltd.

     

    (b) Address of Principal Business office or, if None, Residence

     

    Redmile Group, LLC

    One Letterman Drive

    Building D, Suite D3-300

    The Presidio of San Francisco

    San Francisco, California 94129

     

    Jeremy C. Green

    c/o Redmile Group, LLC (NY Office)

    45 W. 27th Street, Floor 11

    New York, NY 10001

     

    RedCo II Master Fund, L.P.

    c/o Redmile Group, LLC

    One Letterman Drive

    Building D, Suite D3-300

    The Presidio of San Francisco

    San Francisco, California 94129

     

    Redmile Strategic Trading Sub, Ltd.
    c/o Redmile Group, LLC
    One Letterman Drive
    Building D, Suite D3-300
    The Presidio of San Francisco
    San Francisco, California 94129

     

    (c) Citizenship

     

    Redmile Group, LLC: Delaware
    Jeremy C. Green: United Kingdom

    RedCo II Master Fund, L.P.: Cayman Islands

    Redmile Strategic Trading Sub, Ltd.: Cayman Islands

     

     

     

     

    (d) Title of Class of Securities

     

    Common Stock, $0.001 par value

     

    (e) CUSIP Number

     

    80706P103

     

      Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

      (a) ¨  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

      (b) ¨  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

      (c) ¨  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

      (d) ¨  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

      (e) ¨  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

      (f) ¨  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

      (g) ¨  A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

      (h) ¨  A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

      (j) ¨  A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

      (k) ¨  Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

     

    Item 4. Ownership.

     

    (a) Amount beneficially owned:
         
        Redmile Group, LLC – 7,706,883 *
        Jeremy C. Green – 7,706,883 *
        RedCo II Master Fund, L.P. – 3,209,901 ***
        Redmile Strategic Trading Sub, Ltd. – 897,112 ****
         
      (b) Percent of class:
         
        Redmile Group, LLC – 9.9% **
        Jeremy C. Green – 9.9% **
        RedCo II Master Fund, L.P. – 4.2% **
        Redmile Strategic Trading Sub, Ltd. – 1.2% ****

     

     

     

     

      (c) Number of shares as to which Redmile Group, LLC has:

     

      (i) Sole power to vote or to direct the vote:

     

    0

     

      (ii) Shared power to vote or to direct the vote:

     

    7,706,883 *

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    0

     

      (iv) Shared power to dispose or to direct the disposition of:

     

    7,706,883 *

     

    Number of shares as to which Jeremy C. Green has:

     

      (i) Sole power to vote or to direct the vote:

     

    0

     

      (ii) Shared power to vote or to direct the vote:

     

    7,706,883 *

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    0

     

      (iv) Shared power to dispose or to direct the disposition of:

     

    7,706,883 *

     

    Number of shares as to which RedCo II Master Fund, L.P. has:

     

      (i) Sole power to vote or to direct the vote:

     

    0

     

      (ii) Shared power to vote or to direct the vote:

     

    3,209,901 ***

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    0

     

      (iv) Shared power to dispose or to direct the disposition of:

     

    3,209,901 ***

     

    Number of shares as to which Redmile Strategic Trading Sub, Ltd. has:

     

      (i) Sole power to vote or to direct the vote:

     

    0

     

      (ii) Shared power to vote or to direct the vote:

     

    897,112 ****

     

     

     

      (iii) Sole power to dispose or to direct the disposition of:

     

    0

     

      (iv) Shared power to dispose or to direct the disposition of:

     

    897,112 ****

     

      * Redmile Group, LLC’s and Jeremy C. Green’s beneficial ownership of Common Stock is comprised of 6,402,505 shares of Common Stock owned by the Redmile Funds, including RedCo II Master Fund, L.P. and Redmile Strategic Trading Sub, Ltd., which shares of Common Stock may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Funds. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Subject to the Beneficial Ownership Blocker, Mr. Green may also be deemed to beneficially own 12,712,595 shares of Common Stock issuable upon exercise of the Warrants. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The 7,706,883 shares of Common Stock reported as beneficially owned by Redmile Group, LLC in this Schedule 13G represents 9.99% of the outstanding shares of Common Stock.

     

    ** Percentage based on (i) 72,143,258 shares of Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q, plus (ii) 1,304,378 shares of Common Stock issuable upon exercise of certain of the Warrants, which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of the Warrants, plus (iii) 3,698,343 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 2, 2023 to December 31, 2023.

     

    *** RedCo II Master Fund, L.P.’s beneficial ownership of the Issuer’s Common Stock is comprised of 1,905,523 shares of Common Stock. Subject to the Beneficial Ownership Blocker, RedCo II Master Fund, L.P. also beneficially owns 10,655,102 shares of Common Stock issuable upon exercise of the Warrants directly held by RedCo II Master Fund, L.P. Pursuant to the terms of the Warrants, the Issuer may not effect any exercise of any Warrant, and a holder of a Warrant does not have the right to exercise any portion of the Warrant held by such holder, if the Beneficial Ownership Blocker applies. The shares of Common Stock reported as beneficially owned by RedCo II Master Fund, L.P. in this Schedule 13G represent the shares of Common Stock held directly by RedCo II Master Fund, L.P. and the 1,304,378 shares of Common Stock that could be issued to RedCo II Master Fund, L.P. upon exercise of certain of the Warrants directly held by RedCo II Master Fund, L.P. under the Beneficial Ownership Blocker. Percentage based on the sum of (i) 72,143,258 shares of Common Stock outstanding as of November 2, 2023, as reported in the Issuer’s Form 10-Q, plus (ii) 1,304,378 shares of Common Stock issuable upon exercise of the Warrants directly held by RedCo II Master Fund, L.P., which due to the Beneficial Ownership Limitation is the maximum number of shares that could be issued upon exercise of the Warrants, plus (iii) 3,698,343 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 2, 2023 to December 31, 2023.

     

    **** Redmile Strategic Trading Sub, Ltd. beneficially owns 491,939 shares of Common Stock and 405,173 shares of Common Stock issuable upon exercise of the Warrants directly held by Redmile Strategic Trading Sub, Ltd. Percentage based on: (i) 72,143,258 shares of Common Stock outstanding as of November 2, 2023, as reported by the Issuer in the Form 10-Q plus (ii) 405,173 shares of Common Stock issuable upon exercise of certain of the Warrants directly held by Redmile Strategic Trading Sub, Ltd., plus (iii) 3,698,343 shares of Common Stock issued to the Redmile Funds upon exercise of certain additional Warrants during the period after November 2, 2023 to December 31, 2023.

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

     

    See the response to Item 4.

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A.

     

    Item 9. Notice of Dissolution of Group.

     

    N/A.

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024

     

     

    Redmile Group, LLC

         
      By: /s/ Jeremy C. Green
       

    Name: Jeremy C. Green

    Title: Managing Member

     

      RedCo II Master Fund, L.P.
      By: RedCo II (GP), LLC, its general partner
       
        /s/ Jeremy C. Green  
        Name: Jeremy C. Green
        Title: Managing Member  

     

     

    Redmile Strategic Trading Sub, Ltd.

    By: Redmile Group, LLC, its investment manager

     
      /s/ Jeremy C. Green
      Name: Jeremy C. Green
      Title: Authorized Person

     

      /s/ Jeremy C. Green
     

    Jeremy C. Green 

     

     

     

    Get the next $SRRK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRRK

    DatePrice TargetRatingAnalyst
    9/15/2025$51.00Outperform
    Leerink Partners
    8/21/2025$50.00Buy
    Jefferies
    7/30/2025$53.00Strong Buy
    Raymond James
    7/17/2025Overweight
    Cantor Fitzgerald
    11/26/2024$40.00 → $50.00Buy
    H.C. Wainwright
    10/7/2024$30.00 → $35.00Buy
    H.C. Wainwright
    3/28/2024$30.00Strong Buy
    Raymond James
    10/25/2023$20.00Hold → Buy
    Jefferies
    More analyst ratings

    $SRRK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding Corporation

    SCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    8/14/25 1:07:20 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Scholar Rock Holding Corporation

    10-Q - Scholar Rock Holding Corp (0001727196) (Filer)

    8/6/25 7:16:31 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Scholar Rock Holding Corp (0001727196) (Filer)

    8/6/25 7:15:15 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Scholar Rock with a new price target

    Leerink Partners initiated coverage of Scholar Rock with a rating of Outperform and set a new price target of $51.00

    9/15/25 8:09:44 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on Scholar Rock with a new price target

    Jefferies resumed coverage of Scholar Rock with a rating of Buy and set a new price target of $50.00

    8/21/25 8:19:20 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Raymond James resumed coverage on Scholar Rock with a new price target

    Raymond James resumed coverage of Scholar Rock with a rating of Strong Buy and set a new price target of $53.00

    7/30/25 7:34:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SRRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 120,800 shares of its common stock to 9 newly hired employees, consisting of inducement stock options to purchase an aggregate of 69,029 shares of common stock and inducement restricted stock units, covering an aggregate of 51,771 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Comp

    9/12/25 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of its common stock to 64 newly hired employees, consisting of inducement stock options to purchase an aggregate of 243,577 shares of common stock and inducement restricted stock units, covering an aggregate of 182,673 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the C

    8/15/25 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

    First and only muscle-targeted SMA therapy to demonstrate statistically significant, clinically meaningful improvements on the gold-standard HFMSE scale (p=0.019) versus placebo, with consistent benefits across pre-specified subgroups (age, type of SMN-targeted treatment, and SMN-targeted treatment initiation age) and region 30.4% of patients receiving apitegromab had ≥ 3-point improvement in HFMSE versus 12.5% of patients on placebo, despite all study patients receiving chronic, ongoing SMN-targeted treatment 19.6% of patients receiving apitegromab had ≥ 4-point improvement in their HFMSE score versus 6.3% of patients on placebo, despite all study patients receiving chronic, ongoing

    8/14/25 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Akkaraju Srinivas bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:46:02 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Samsara Biocapital Gp, Llc bought $15,000,000 worth of shares (2,189,781 units at $6.85) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/18/23 5:44:33 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Invus Public Equities, L.P. bought $15,086,736 worth of shares (2,199,931 units at $6.86) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    10/16/23 5:46:56 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHRO Parlavecchio Caryn sold $67,880 worth of shares (2,178 units at $31.17), decreasing direct ownership by 1% to 155,464 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    8/19/25 4:30:21 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Flier Jeffrey S. sold $445,688 worth of shares (11,136 units at $40.02) (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    7/18/25 4:15:07 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF SCIENTIFIC OFFICER Qatanani Mo sold $828,898 worth of shares (24,066 units at $34.44), decreasing direct ownership by 17% to 115,495 units (SEC Form 4)

    4 - Scholar Rock Holding Corp (0001727196) (Issuer)

    7/10/25 9:46:38 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Leadership Updates

    Live Leadership Updates

    View All

    Scholar Rock Appoints Caryn Parlavecchio as Chief Human Resources Officer

    - Former Vice President and Global HR Head of Oncology and Pharma Development at Novartis brings extensive leadership experience focused on talent, culture, and diversity Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Caryn Parlavecchio as Chief Human Resources Officer. She will join the executive team, bringing more than 20 years of experience as a senior leader and strategic executive in the biotechnology and pharmaceutical industries. This press release features multimedia. View the full release here: https://www.businesswire.co

    8/16/21 4:05:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Financials

    Live finance-specific insights

    View All

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 120,800 shares of its common stock to 9 newly hired employees, consisting of inducement stock options to purchase an aggregate of 69,029 shares of common stock and inducement restricted stock units, covering an aggregate of 51,771 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Comp

    9/12/25 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Scholar Rock (NASDAQ:SRRK, the "Company")), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that the company granted inducement equity awards covering an aggregate of 426,250 shares of its common stock to 64 newly hired employees, consisting of inducement stock options to purchase an aggregate of 243,577 shares of common stock and inducement restricted stock units, covering an aggregate of 182,673 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the C

    8/15/25 4:15:00 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

    First and only muscle-targeted SMA therapy to demonstrate statistically significant, clinically meaningful improvements on the gold-standard HFMSE scale (p=0.019) versus placebo, with consistent benefits across pre-specified subgroups (age, type of SMN-targeted treatment, and SMN-targeted treatment initiation age) and region 30.4% of patients receiving apitegromab had ≥ 3-point improvement in HFMSE versus 12.5% of patients on placebo, despite all study patients receiving chronic, ongoing SMN-targeted treatment 19.6% of patients receiving apitegromab had ≥ 4-point improvement in their HFMSE score versus 6.3% of patients on placebo, despite all study patients receiving chronic, ongoing

    8/14/25 8:00:00 AM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SRRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 9:00:58 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 7:24:55 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Scholar Rock Holding Corporation

    SC 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)

    11/14/24 1:22:38 PM ET
    $SRRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care